Hennigsdorf/Berlin (Germany), September 8, 2023 – Adrenomed AG, the vascular integrity company, today announced new findings on the biomarker-guided treatment of septic shock with enibarcimab. New data analyses of the phase II clinical trial AdrenOSS-2 validate
The article was published by Victoria English, MedNous, Evernow Publishing, www.mednous.com
Hennigsdorf/Berlin (Germany), February 1, 2023 – Adrenomed AG, the vascular integrity company, today announced the appointment of Dr. Stephan Witte as Chief Medical Officer (CMO) of Adrenomed. Dr. Stephan Witte is a drug development professional
J.P. Morgan Healthcare Conference & Biotech Showcase 9-12 January | San Francisco, California, USA Meet the Adrenomed team in San Francisco Link to J.P.Morgan Healthcare Conference Link to Biotech Showcase
By loading the map, you agree to Google's privacy policy.
Learn more
© 2022 Adrenomed AG | Imprint/Impressum | Legal Notice/Datenschutzerklärung
